Parib 50 mg (Capsule)
Unit Price: ৳ 800.00 (1 x 112: ৳ 89,600.00)
Strip Price: ৳ 89,600.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Olaparib |
| Company | Drug international ltd |
| Also available as |
Indications
- Breast cancer treatment
- Ovarian cancer treatment
- Monotherapy
- Metastatic breast cancer
- Platinum sensitive relapsed cancer
- Neoadjuvant chemotherapy
Pharmacology
- Inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes
- DNA repair inhibition
- Anti-tumor activity
- Metabolism by CYP3A4/5
- Excretion in urine and feces
- Protein binding of approximately 82%
Dosage & Administration
- Recommended dose: 400 mg twice daily
- Dose modifications for adverse reactions
- Dose modifications for CYP3A inhibitors
- Dose modifications for renal impairment
- Pediatric use not established
Interaction
- Potentiation of myelosuppressive toxicity with anticancer agents
- Drugs increasing Olaparib plasma concentrations
- Drugs decreasing Olaparib plasma concentrations
Contraindications
- Hypersensitivity to Olaparib or its ingredients
Side Effects
- Most common serious adverse reaction: anemia
- Proportion of patients discontinuing due to adverse events
- Reported serious ADRs: dermatitis allergic, neutrophil count decreased, platelet count decreased
Pregnancy & Lactation
- Potential fetal harm
- Potential risk for loss of pregnancy
- Unknown excretion in human milk
Precautions & Warnings
- Incidence of Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) <1.5%
- Pneumonitis risk <1%
Overdose Effects
- No specific treatment established
- General supportive measures
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Store below 30°C, protect from light, keep out of reach of children